CYP2C19 genotype-guided strategy (with clopidogrel being assigned to noncarriers of CYP2C19*2 or CYP2C19*3 loss-of-function) was associated with a lower risk of bleeding (HR 0.78, 95% CI 0.61–0.98; p = 0.04) and was non-inferior to standard treatment with ticagrelor or prasugrel at 12 months in terms of death from any cause, MI, definite stent thrombosis, or stroke (absolute difference, −0.7%; 95% CI, −2.0 to 0.7; pnon-inferiority < 0.001). The gene discussed is CYP2C19; the disease is stroke disorder.